Baymount Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Baymount Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,500	Closed	-$353K	–	15
2023 Q1	$353K	Buy	+7,500	New	+$622K	0.58%	12
2022 Q2	–	Sell	-1,250,000	Closed	-$112M	–	4
2022 Q1	$112M	Buy	+1,250,000	New	+$115M	54.29%	1
2020 Q4	–	Sell	-50,000	Closed	-$5.57M	–	13
2020 Q3	$5.57M	Hold	50,000	–	–	7.78%	6
2020 Q2	$5.6M	Buy	+50,000	New	+$4.92M	4.84%	7

Other funds holding XBI

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Baymount Management's XBI Position: Q2 2024 in Review

Baymount Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2024, closing a stake of 360,000 shares — an estimated $34.2M sold.

Baymount Management first reported a position in XBI in Q1 2024 and held it in 1 quarter. The position peaked at $34.2M in Q1 2024. 761 funds tracked by Wall St. Rank hold XBI as of Q2 2024.

Baymount Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2024 after selling out during the quarter.
Baymount Management sold 360,000 State Street SPDR S&P Biotech ETF shares in Q2 2024, an estimated $34.2M.
Baymount Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2024 and held it in 1 quarter.
Baymount Management's State Street SPDR S&P Biotech ETF position peaked at $34.2M in Q1 2024.
761 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2024.

Based on Baymount Management's 13F filing for Q2 2024.